Date Seed Extract Effectiveness in Controlling Diabetes and Cardiovascular Risk in T2DM

StatusUnknown
PhaseNot applicable
Started

Record status This record was last updated September 19, 2024 (before its estimated February 1, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Minor Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
5,101 trials monitored
See 233 trials at risk
3,888 trials monitored
See 157 trials at risk
2,236 trials monitored
See 113 trials at risk
Globally, chronic noncommunicable diseases rank as the leading cause of morbidity and mortality. Diabetes is reaching high epidemic proportions across the globe. The prevalence of diabetes is increasing in Saudi Arabia, with diabetes affecting 14.1% of the population across all age groups and 28% of those over the age of 30. Date seed intake is one of the best-studied patterns. Previous studies findinds showed that the phenolic compounds in date seeds have blood sugar-lowering properties. There is a lack of data on how date seed diets may affect glycaemia control and cardiovascular risk among Saudi Arabian patients with T2DM. Therefore, randomised controlled trials (RCTs) will be conducted to assess the effects of date seeds on glycaemic control and cardiovascular risk among diabetes patients.
Trial Details
NCT Number NCT06590519
Lead Sponsor Universiti Putra Malaysia
Conditions
(from sponsor)
Type 2 Diabetes Mellitus, Obesity
Related terms Diabetes Mellitus, Type 2, Obesity
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov